Stockreport

Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar ...

Wave Life Sciences Ltd. - Ordinary Shares  (WVE) 
Last wave life sciences ltd. - ordinary shares earnings: 3/2 06:45 am Check Earnings Report
PDF Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in viscer [Read more]